TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
RDY

Dr. Reddy’s Laboratories Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

12.30$ +0.0% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Cash Flow

Dr. Reddy’s Laboratories Ltd (RDY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -927 million INR. Tick rows to compare them in a chart.

All figures in millions of INR.

Tick rows to compare them in a chart (up to 4)

Cash Flow RDY
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
2,709 5,233 8,517 -1,979 6,707 7,520 5,781 -5,022 10,728 16,287 6,711 9,833 10,106 7,356 29 10,913 9,254 4,270 153 -3,448 5,106 17,331 9,119 6,655 9,281 23,260 19,677 11,250 17,926 4,737 136 8,496 9,316 6,620 21,996 14,629 15,573 10,908 15,438 -927 40,992
2,847 2,891 2,858 2,799 2,941 2,972 2,998 2,983 2,998 3,108 3,101 3,083 3,339 3,085 41 3,140 3,271 3,216 43 2,905 2,985 2,976 2,958 3,050 3,126 3,271 3,055 3,569 3,789 3,770 45 3,810 3,975 4,719 4,554 4,765 5,051 5,213 5,663 5,372 21,299
82 127 112 120 101 123 110 84 80 113 112 143 167 127 127 143 161 151 129 147 143 161 141 146 117 113 21 108 103 99 97 101 107 103 113 112 100 20 94 97 311
– – 3,499 146 1,332 2,227 27 1.2 -2.5 0.0 1,674 217 -2,069 11,916 -4,657 2,547 993 7,807 699 12 -853 635 6,836 -1,698 4,811 1,494 -3,272 -3,272 -3,272 – – – – – – – – – – – –
-3,076 -3,991 1,391 -5,515 -415 -1,023 -2,011 -12,651 2,877 6,411 -2,408 -421 -2,673 -1,948 -48 -567 -2,633 -6,951 25 -12,073 -6,946 15,181 -14,660 -6,573 -9,784 6,024 2,478 -8,174 2,609 -11,855 -33 -13,141 -7,784 -9,648 584 -8,191 -2,556 -8,126 7,779 -11,997 -14,900
26,737 3,098 3,352 3,059 2,997 3,340 1,647 2,307 2,137 1,730 1,317 1,439 1,199 1,380 12 1,891 2,675 4,792 40 3,337 7,211 4,474 4,027 8,690 3,329 3,099 3,746 12,171 3,939 5,042 63 6,424 7,909 8,819 11,246 10,147 10,135 7,320 4,689 3,702 25,846
-26,037 2,061 -3,240 -227 -5,229 -10,224 797 3,462 -2,925 0.0 -572 -3,691 -1,201 8,139 -115 -15,724 -1,246 3,760 -132 -5,607 3,969 -2,761 -21,988 -4,923 5,733 -25,600 -15,771 -8,236 -12,753 – -142 -20,248 -19,071 -5,458 -13,300 -19,192 -9,543 -10,292 -28,222 3,836 -44,221
3,390 50 78 4.0 3,992 63 675 1.0 4,003 0.0 1.0 0.0 3,916 3,916 0.2 4,147 4,147 4,147 0.5 4,146 4,146 4,146 4,146 4,979 4,979 4,979 4,979 6,648 6,648 0.0 0.0 0.0 6,662 0.0 6,662 0.0 6,659 113 41 0.0 6,813
– – 1.0 1.0 1.0 1.0 0.0 0.0 -64 -432 -39 -474 -474 -471 0.0 92 -190 59 -14 147 281 326 334 31 66 147 368 – 765 – 805 – 157 – -1,389 – 288 – – – –
– – 16,316 1,600 2,430 2,543 -87 23 -26 0.0 -5,142 -5,417 -3,647 -15,868 5,767 7,372 -4,037 -7,190 9,949 2,456 -2,926 -2,197 5,402 -10,290 -7,071 1,094 -991 -991 -587 – – – 16,555 1,521 -5,146 -256 2,366 8,683 8,200 -5,821 13,428
19,516 -3,520 -7,396 1,291 -1,937 2,243 -6,037 1,194 -6,339 -10,572 -5,609 -6,313 -7,980 -16,303 83 7,181 -8,565 -7,554 121 2,261 -7,212 -2,568 5,097 -10,800 -12,346 583 -4,298 -1,476 -7,036 5,282 1.7 9,541 16,150 590 -7,370 -1,203 -5,323 7,777 8,738 -7,117 4,075
-4,028 3,725 -2,252 -954 -425 -475 617 -373 1,603 -2,072 528 -163 943 -764 -4.3 2,438 -612 533 144 -6,652 1,812 11,996 -7,124 -8,555 2,796 -2,834 -480 1,449 6,307 -6,000 -5.3 -2,194 6,372 1,747 1,561 -5,589 902 8,751 -4,235 -4,169 1,249
-24,028 2,135 5,165 -5,038 3,710 4,180 4,134 -7,329 8,591 14,557 5,394 8,394 8,907 5,976 18 9,022 6,579 -522 114 -6,785 -2,105 12,857 5,092 -2,035 5,952 20,161 15,931 -921 13,987 -305 73 2,072 1,407 -2,199 10,750 4,482 5,438 3,588 10,749 -4,629 15,146

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?